UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer

Reuters

10/02

<a href="https://laohu8.com/S/URGN">UroGen</a> Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer

UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2572149595"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2572149595\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2572149595?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-10-02 20:00","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2572149595","market":"nz","top_or_hot":-1,"title":"UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nUroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non–Muscle Invasive Bladder Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-10-02 20:00</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/URGN\">UroGen</a> Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"URGN","symbol_name":"烏龍製藥","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251002:nNDL9dcpJh:1","article_id":"2572149595","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2572149595","pubTimestamp":1759406457,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"UroGen Pharma Announces Positive Clinical Results for ZUSDURI in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer. UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI  for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer . The review, published in the peer-reviewed journal *Reviews in Urology*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.Disclaimer: This news brief was created by Public Technologies  using generative artificial","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"URGN":"乌龙制药","BK4139":"生物科技","LU2210150020.SGD":"Natixis Thematics Subscription Economy R/A SGD","IE00BKPKM429.USD":"NEUBERGER BERMAN GLOBAL SUSTAINABLE EQUITY \"A\" (USD) ACC","IE00BGHQF748.EUR":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (EUR) ACC","IE00B64PRP62.GBP":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (GBP) ACC","LU0314104364.USD":"MANULIFE GF AMERICAN GROWTH \"AA\" (USD) INC","LU2210149790.SGD":"Natixis Thematics Subscription Economy R/A SGD-H","NDAQ":"纳斯达克OMX交易所","BK4112":"金融交易所和数据","LU2095319765.USD":"Natixis Thematics Subscription Economy R/A USD","BK4585":"ETF&股票定投概念","IE00B3QW5Z07.USD":"GUINNESS GLOBAL MONEY MANAGERS \"C\" (USD) ACC","BK4588":"碎股"},"translate_title":"UroGen Pharma宣布ZUSDURI的积极临床结果™复发性低级别、中等风险非肌层浸润性膀胱癌","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"NDAQ":0.9,"URGN":0.9},"content_text":"UroGen Pharma Announces Positive Clinical Results for ZUSDURI™ in Recurrent Low-Grade, Intermediate-Risk Non-Muscle Invasive Bladder Cancer\n    \n\n        UroGen Pharma Ltd. has announced the publication of a comprehensive clinical review of ZUSDURI™ (mitomycin) for intravesical solution, the first and only FDA-approved medication for adults with recurrent, low-grade, intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC). The review, published in the peer-reviewed journal *Reviews in Urology™*, summarizes data from three late-phase clinical trials-OPTIMA II, ATLAS, and ENVISION-evaluating the safety and efficacy of ZUSDURI in this patient population. Results from these studies have already been presented and indicate complete response rates between 64.8% and 79.6% at three months. ZUSDURI is administered as a non-surgical, outpatient treatment and is reported to have a safety profile manageable in routine urologic practice.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Urogen Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9538923-en) on October 02, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"dataReport","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}